EOS789 是一种口服有效的钠依赖性磷酸转运蛋白抑制剂,对人 NaPi-IIb、PiT-1、PiT-2 的 IC50 值分别为 6.8、1.5 和 1.7 μM,对大鼠 NaPi-IIb、PiT-1、PiT-2 的 IC50 分别为 3.9、1.9 和 1.7 μM,可抑制肠道磷吸收、增加粪便磷排泄、减少尿磷排泄、降低血清磷酸盐、FGF23 和成体甲状旁腺激素水平,并可改善异位胸主动脉钙化、肾脏损伤和高磷血症、抑制纤维化标志物的表达,因此可用于研究高磷血症及慢性肾脏病-矿物质骨病 (CKD-MBD)。
产品编号: MS-F95711 纯度: 99.14% CAS No.: 1628848-73-6 分子式: C35H36F8N6O5 分子量: 772.70
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

EOS789 是一种口服有效的钠依赖性磷酸转运蛋白抑制剂,对人 NaPi-IIb、PiT-1、PiT-2 的 IC50 值分别为 6.8、1.5 和 1.7 μM,对大鼠 NaPi-IIb、PiT-1、PiT-2 的 IC50 分别为 3.9、1.9 和 1.7 μM,可抑制肠道磷吸收、增加粪便磷排泄、减少尿磷排泄、降低血清磷酸盐、FGF23 和成体甲状旁腺激素水平,并可改善异位胸主动脉钙化、肾脏损伤和高磷血症、抑制纤维化标志物的表达,因此可用于研究高磷血症及慢性肾脏病-矿物质骨病 (CKD-MBD)。

生物实验数据

生物活性 EOS789 is an orally effective inhibitor of sodium-dependent phosphate transporters with IC50 values of 6.8, 1.5, and 1.7 μM for human NaPi-IIb, PiT-1, and PiT-2, respectively, and 3.9, 1.9, and 1.7 μM for rat NaPi-IIb, PiT-1, and PiT-2, respectively; it inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, lowers serum phosphate, FGF23, and adult parathyroid hormone levels, ameliorates ectopic thoracic aortic calcification, kidney injury, and hyperphosphatemia, and suppresses the expression of fibrosis markers, and can therefore be used for research on hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD).
体外研究
(In Vitro)

EOS789 可抑制正常大鼠肠刷状缘膜囊泡的磷酸盐摄取,其 IC50 为 3.1 μM。
EOS789 (0.3-3.0 μM; 24 h) 可剂量依赖性地抑制高磷酸盐诱导的人肾小球系膜细胞 hMes 130hT-9 中 Collagen 1A1、Collagen 3A1 及 α-平滑肌肌动蛋白 mRNA 的上调。

Real Time qPCR

Cell Line: hMes 130hT-9 immortalized human mesangial cells
Concentration: 0.3 μM, 1.0 μM, 3.0 μM
Incubation Time: 24 h
Result: Significantly suppressed Collagen 1A1 relative expression at 1.0 μM and 3.0 μM.
Significantly suppressed Collagen 3A1 relative expression at 1.0 μM and 3.0 μM.
Significantly suppressed α-smooth muscle actin relative expression at 3.0 μM.
Showed a dose-dependent inhibitory effect on all three fibrotic marker genes.
体内研究
(In Vivo)

EOS789 (0.050-0.50%;口服;每日一次;连续 3 天) 可剂量依赖性地增加正常雄性 Wistar 大鼠的粪便磷排泄量、减少尿磷排泄量并降低血清磷水平,证实其可抑制肠道磷吸收。
EOS789 (0.015-1.0%;口服;每日一次;连续 14 天) 可剂量依赖性降低腺嘌呤诱导的高磷血症雄性 Wistar 大鼠的血清磷酸盐、FGF-23 和完整 PTH 水平,增加粪便磷排泄量并减少尿磷排泄量,且在等效剂量下其效力优于 NaPi-IIb 选择性抑制剂。
EOS789 (0.3%;口服;自由摄取;第 21 天至第 116 天) 可持续性抑制慢性抗 Thy1.1 肾炎雄性 Fisher 大鼠的血清磷酸盐、FGF-23 及完整 PTH 水平,改善主动脉钙化,降低血清肌酐水平,并改善肾脏组织病理学及纤维化基因表达。
EOS789 (0.3%;食物掺混;自由摄取;5 周) 可显著改善抗 GBM 诱导的肾小球肾炎大鼠的高磷血症、提升肾功能并减少肾小球新月体形成,同时可使血清肌酐显著降至 1.31 mg/dL,肾小球新月体形成占总肾小球的比例降至 66.1%。

Animal Model: Crlj:WI (Wistar) (male)
Dosage: 0.050%, 0.15%, 0.50%
Administration: p.o.; daily; 3 days
Result: Increased fecal 33P excretion rate from ~45% to ~55%.
Decreased urinary 33P excretion rate from ~4.5% to ~3%.
Decreased serum 33P radioactivity from ~3900 dpm/mL to ~3500 dpm/mL.
Increased fecal 33P excretion rate to ~60%.
Decreased urinary 33P excretion rate to ~2.2%.
Decreased serum 33P radioactivity to ~3200 dpm/mL.
Increased fecal 33P excretion rate to ~70%.
Decreased urinary 33P excretion rate to ~1.2%.
Decreased serum 33P radioactivity to ~2700 dpm/mL.
Animal Model: Crlj:WI (Wistar) (male, adenine-induced hyperphosphatemia)
Dosage: 0.015%, 0.05%, 0.15%, 0.50%, 1.0%
Administration: p.o.; daily; 14 days
Result: Reduced serum phosphate from 9.7 mg/dl to ~7.5 mg/dl.
Reduced serum FGF-23 from ~10,000 pg/mL to ~1500 pg/mL.
Reduced serum intact PTH from ~700 pg/mL to ~450 pg/mL.
Reduced serum phosphate to ~6.8 mg/dl.
Reduced serum FGF-23 to ~1200 pg/mL.
Reduced serum intact PTH to ~350 pg/mL.
Reduced serum FGF-23 to ~800 pg/mL.
Reduced serum intact PTH to ~400 pg/mL.
Reduced serum FGF-23 to ~150 pg/mL.
Reduced serum intact PTH to ~100 pg/mL.
Reduced serum phosphate to ~6.5 mg/dl.
Increased fecal phosphorus excretion from ~78 mg/4d to ~120 mg/4d.
Decreased urinary phosphorus excretion from ~3.5 mg/d to near 0 mg/d.
Animal Model: F344/DuCrlCrlj (Fisher) (male, anti-Thy1.1-induced chronic kidney disease-mineral bone disorder)
Dosage: 0.1%, 0.3%
Administration: p.o.; ad libitum; day 21 to day 116
Result: Reduced serum phosphate from ~12 mg/dl to ~10 mg/dl at study end.
Did not significantly reduce serum FGF-23 or intact PTH levels.
Showed no significant reduction in aortic calcium content.
Reduced serum phosphate to ~8 mg/dl.
Reduced serum FGF-23 from ~240,000 pg/mL to ~5000 pg/mL.
Reduced serum intact PTH from ~8000 pg/mL to ~4000 pg/mL.
Reduced serum creatinine from ~3.2 mg/dl to ~2.4 mg/dl.
Suppressed aortic calcium content to near normal levels, with no histopathologic calcification observed in any treated rats.
Reduced glomerulosclerosis score from 2.60 to 2.32, degeneration of tubules score from 2.54 to 2.23, and tubulointerstitial fibrosis score from 2.39 to 2.01.
Significantly reduced renal mRNA expression of TGF-β1, collagen type 1 α1, collagen type 3 α1, and α-smooth muscle actin versus disease control (0.3% dose).
Animal Model: Wistar (male, 7 weeks old, anti-rat GBM antibody-induced glomerulonephritis)
Dosage: ~100 mg/kg/day; ~200 mg/kg/day
Administration: food admixture; ad libitum; 5 weeks
Result: Dose-dependently suppressed the disease-induced increase in serum phosphate.
Increased fecal phosphate excretion significantly to 89.1 mg/day.
Decreased fractional urinary phosphate excretion significantly to 18.5%.
Significantly suppressed serum FGF23 increase.
Significantly improved severely reduced serum calcitriol.
Decreased serum creatinine significantly to 1.31 mg/dL.
Decreased urinary fractional excretion of albumin significantly to 0.04%.
Decreased serum sodium significantly to 140.5 mEq/L.
Decreased urinary fractional excretion of sodium significantly to 1.15%.
Decreased glomerular crescent formation significantly to 66.1% of total glomeruli.
Significantly increased body weight compared to disease control.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 772.70
分子式 C35H36F8N6O5
CAS No. 1628848-73-6

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (129.42 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.2942 mL6.4708 mL12.9416 mL32.3541 mL
5 mM0.2588 mL1.2942 mL2.5883 mL6.4708 mL
10 mM0.1294 mL0.6471 mL1.2942 mL3.2354 mL
15 mM0.0863 mL0.4314 mL0.8628 mL2.1569 mL
20 mM0.0647 mL0.3235 mL0.6471 mL1.6177 mL
25 mM0.0518 mL0.2588 mL0.5177 mL1.2942 mL
30 mM0.0431 mL0.2157 mL0.4314 mL1.0785 mL
40 mM0.0324 mL0.1618 mL0.3235 mL0.8089 mL
50 mM0.0259 mL0.1294 mL0.2588 mL0.6471 mL
60 mM0.0216 mL0.1078 mL0.2157 mL0.5392 mL
80 mM0.0162 mL0.0809 mL0.1618 mL0.4044 mL
100 mM0.0129 mL0.0647 mL0.1294 mL0.3235 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础